Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II erlotinib + bevacizumab first-line study in advanced NSCLC
NL-OMON22641Phase 2Active, not recruiting
- Sponsor
- Roche
- Start
- Jan 2006
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib and bevacizumab in non-small cell lung cancer (NSCLC), sponsored by Roche. Primary endpoint: Rate of no progression at 6 weeks. Started Jan 2006; status: active, not recruiting.
02
Drugs
erlotinibbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON22641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON22641.